The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
The burden of high drug costs is something that everyone with health insurance coverage is facing, explained Leigh Purvis, director, Health Services Research, AARP Public Policy Institute.
Transcript
How does the burden of high prescription drug costs in Medicare have a broader impact than just on Medicare beneficiaries?
This problem is not unique to Medicare. This is something that everyone who has health insurance coverage is facing, and frankly, all Americans are facing. A message we always like to drive home when it comes to prescription drug costs is that it’s an issue that affects everyone. You’re either paying for them at the pharmacy counter, you’re paying for them as part of your premiums or part of your cost-sharing as someone with health coverage, or you’re paying for them through your taxes. Programs like Medicare and Medicaid are spending a lot of money of these products, and that eventually will translate into taxes, and ultimately can turn into either higher taxes or cuts to the programs that people rely on.
How does the drug cost burden facing the US elderly population compare with the elderly population in other, similar countries?
I think high prescription drug costs are a challenge globally, but I think they’re much more so in the United States. We face much higher cost-sharing, we have higher cost-related non-adherence. Just the nature of the health coverage system in the United States is much more fragmented. It makes it harder for them to drive bargains on prices that other countries are able to do just by virtue of the fact that they’re bargaining on the behalf of everyone.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More